CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial.
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
多发性骨髓瘤患者被随机分配接受抗TIGIT（T细胞免疫受体）或抗LAG3（淋巴细胞活化基因）抗体治疗，随后联合泊马度胺和地塞米松（NCT04150965）。主要终点和次要终点分别为安全性和疗效。治疗耐受良好，未出现剂量限制性毒性。在抗TIGIT组（6名参与者中的3名）和抗LAG3组（6名参与者中的2名）中均观察到持久的临床缓解。抗LAG3缓解者具有更高的初始分化簇4（CD4）阳性T细胞和更低的程序性细胞死亡蛋白1阳性效应T细胞。抗TIGIT缓解者具有更高的CD226表达、NK 细胞活化以及更低的CD112表达。这些数据证明了TIGIT-LAG3阻断的临床活性，并确定了骨髓瘤中通路特异性的缓解相关因素。
Persons with myeloma were randomized to receive an anti-TIGIT (T cell immunoreceptor) or anti-LAG3 (lymphocyte activation gene) antibody followed by combination with pomalidomide and dexamethasone ( NCT04150965 ). Primary and secondary endpoints were safety and efficacy, respectively. Therapy was well tolerated without dose-limiting toxicity. Durable clinical responses were observed in both the anti-TIGIT(three of six participants) and the anti-LAG3 (two of six participants) arms.
Anti-LAG3 responders had higher naive cluster of differentiation 4 (CD4)-positive T cells and lower programmed cell death protein 1-positive effector T cells. Anti-TIGIT responders had higher CD226 expression, natural killer cell activation and lower CD112 expression. These data demonstrate the clinical activity of TIGIT-LAG3 blockade and identify pathway-specific response correlates in myeloma.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
